'''Quadrosilan''' ([[International Nonproprietary Name|INN]], [[British Approved Name|BAN]]) (trade name '''Cisobitan'''; former developmental code name '''KABI-1774''') is a [[Organic compound#Synthetic compounds|synthetic]], [[nonsteroidal]] [[estrogen]] that was developed in the 1970s and that is or has been used as an [[antigonadotropic agent]] in the treatment of [[prostate cancer]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA629|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=629–}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA243|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1|pages=243–}}</ref><ref name="AlfthanAndersson1983">{{cite journal|last1=Alfthan|first1=Olof|last2=Andersson|first2=Lennart|last3=Luigi Esposti|first3=Pier|last4=Dorothea Fosså|first4=Sophie|last5=Arne Gammelgaard|first5=Peter|last6=Erik Gjöres|first6=Jan|last7=Isacson|first7=Sune|last8=Rasmussen|first8=Finn|last9=Ruutu|first9=Mirja|last10=von Schreeb|first10=Tor|last11=Setterberg|first11=Gun|last12=Strandell|first12=Per|last13=Strindberg|first13=Bengt|title=Cisobitan® in Treatment of Prostatic Cancer|journal=Scandinavian Journal of Urology and Nephrology|volume=17|issue=1|year=1983|pages=37–43|issn=0036-5599|doi=10.3109/00365598309179778}}</ref><ref name="Chisholm1985">{{cite journal|last1=Chisholm|first1=Geoffrey D.|title=Treatment of advanced cancer of the prostate|journal=Seminars in Surgical Oncology|volume=1|issue=1|year=1985|pages=38–55|issn=8756-0437|doi=10.1002/ssu.2980010106}}</ref> It is an [[organosilicon]] compound, and is also known as '''2,6-cisdiphenylhexamethylcyclotetrasiloxane'''.<ref name="AlfthanAndersson1983" /><ref name="Apeloig1989">{{cite book|author=Yitzhak Apeloig|title=The Chemistry of Organic Silicon Compounds|url=https://books.google.com/books?id=cf4oAAAAYAAJ|year=1989|publisher=John Wiley & Sons Canada, Limited|isbn=978-0-471-91993-3|page=1154}}</ref> Quadrosilan has estrogenic activity equivalent to that of [[estradiol]],<ref name="MillsShowell2004">{{cite journal|last1=Mills|first1=John S|last2=Showell|first2=Graham A|title=Exploitation of silicon medicinal chemistry in drug discovery|journal=Expert Opinion on Investigational Drugs|volume=13|issue=9|year=2004|pages=1149–1157|issn=1354-3784|doi=10.1517/13543784.13.9.1149}}</ref> and can produce [[feminization (biology)|feminization]] and [[gynecomastia]] as [[side effect]]s in male patients.<ref name="Strindberg1978">{{cite journal|last1=Strindberg|first1=Bengt|title=Biochemical Effects of 2, 6-cis-Diphenylhexamethylcyclotetrasiloxane in Man|year=1978|pages=515–520|doi=10.1007/978-1-4613-4018-8_23}}</ref><ref name="pmid345431">{{cite journal | vauthors = Krarup T, Rasmussen F, Gammelgaard PA | title = Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan) | journal = Scand. J. Urol. Nephrol. | volume = 12 | issue = 1 | pages = 11–5 | year = 1978 | pmid = 345431 | doi = | url = }}</ref>
